Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bioxytran, Inc. (BIXT : OTC)

• Company Description    BioXyTran Inc. is a biotechnology company. It develops anti-necrosis drugs to treat medical conditions resulting from ischemia. The company's product pipeline consists of BXT-25 and BXT-252 which are in clinical stage. BioXyTran Inc. is based in Newton, United States. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $0.10 Daily Weekly Monthly 20 Day Moving Average: 84,248 shares Shares Outstanding: 88.99 (millions) Market Capitalization: $9.01 (millions) Beta: 1.55 52 Week High: $0.23 52 Week Low: $0.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.83% -11.28% 12 Week -43.53% -52.51% Year To Date 12.68% 5.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 2ND AVE SUITE 605 - NEEDHAM,MA 02494 USA ph: 617-454-1199 fax: - mike.sheikh@bioxytraninc.com http://www.bioxytraninc.com

• General Corporate Information    Officers David Platt - Chief Executive Officer; Chairman Ola Soderquist - Chief Financial Officer; Treasurer; Secretary Dale H. Conaway - Director Alan M. Hoberman - Director Radka Milanova - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09075D102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 88.99 Most Recent Split Date: (:1) Beta: 1.55 Market Capitalization: $9.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -2,077.16 12/31/24 - -1,715.13 Current Ratio 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Quick Ratio 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.03 12/31/24 - -0.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©